🎉 A well-deserved recognition for our very own Martine van Vugt, EVP and Chief Strategy Officer, who has been named to this year’s PharmaVoice 100 list! Martine has influenced Genmab’s vision and evolution into a biotech innovation powerhouse. We are proud to celebrate her dedication to impacting patients’ lives. Learn more about this year’s recipients and be inspired by the incredible leaders: http://gmab.ly/Hvtg50TGJZp. #Innovation #PV100 #Leadership
Om os
We are an international biotech company committed to our goal of improving the lives of patients through innovative and differentiated antibody therapeutics. For 25 years, our passionate, innovative and collaborative team has invented next-generation antibody technology platforms and leveraged translational, quantitative, and data sciences, which has resulted in a proprietary pipeline including bispecific T-cell engagers, antibody-drug conjugates, next-generation immune checkpoint modulators, and effector function enhanced antibodies. By 2030, our vision is to transform the lives of people with cancer and other serious diseases with knock-your-socks-off (KYSO®) antibody medicines. We are united by our core values: a passion for innovation, determination, integrity, and working as one team and respecting each other. When you work at Genmab you'll be part of a warm, fun, dynamic community seeking out and embracing the opportunity to build new and bold futures within a rapidly growing biotechnology company. Genmab is a place where you can be authentically you; you are empowered to innovate, build solutions and execute; you feel cared for and supported. In its totality, this makes working at Genmab an extra[not]ordinaryTM experience. Established in 1999, we are headquartered in Copenhagen, Denmark with international presence across North America, Europe and Asia Pacific. For more information, please visit Genmab.com. Disclaimer: http://bit.ly/GENDisclaimer
- Websted
-
http://www.genmab.com
Eksternt link til Genmab
- Branche
- Forskning inden for bioteknologi
- Virksomhedsstørrelse
- 1.001 – 5.000 medarbejdere
- Hovedkvarter
- Copenhagen V
- Type
- Aktieselskab
Beliggenheder
Medarbejdere hos Genmab
-
Hinrich Göhlmann
Scientific Director specializing in 𝐇𝐢𝐠𝐡-𝐃𝐢𝐦𝐞𝐧𝐬𝐢𝐨𝐧𝐚𝐥 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 | Bridging Science, Data, and Technology
-
Amy D.
Director, Digital Products, Experience Management @ Genmab | Digital Transformation | ex-Amex | ex-Regeneron
-
Javier Pintado
Vice President, Global Marketing at Genmab
-
Caroline Eilering
Opdateringer
-
Welcome to Genmab’s October Edition of Knock-Your-Socks-Off-News, a monthly newsletter covering our current happenings across the globe. Follow along with us on our journey for more updates as we advance innovation and continue to work towards our goal of transforming the lives of patients through antibody medicines. #culture #news #healthcare
-
To recognize National Hispanic Heritage Month, we are proud to provide scholarship funding to a local college for students of Hispanic heritage who are studying science. We are looking forward to welcoming guest speaker Dr. Marcia Cruz-Correa, a GI Oncologist and clinical investigator from Puerto Rico, who will share insights on health disparities in the Hispanic community to help educate our colleagues on this important topic. To learn more about our DE&I efforts, click here: http://gmab.ly/M7sS50TtsW1.
-
From developing groundbreaking therapies to fostering supportive communities, we're dedicated to transforming the lives of people with gynecologic and blood cancers through innovative research, patient resources, and community engagement. This September, we recognize both Blood Cancer and Gynecologic Cancer Awareness Months. At Genmab, we're committed to raising awareness, amplifying patient voices and driving progress in these disease areas. Learn more about how we're working toward a brighter future for patients: http://gmab.ly/Twy250TtGsZ #BloodCancerAwarenessMonth #GCAM #CervicalCancer #Lymphoma
Recognizing Those Impacted by Gynecologic and Blood Cancers this September
genmab.com
-
Genmab launches “AI Everywhere” with ChatGPT Enterprise, supported by OpenAI’s commitment to security and privacy. Working with OpenAI means Genmab has the hands-on ability to share a mission to advance and accelerate scientific programs. Click here to learn more: http://gmab.ly/7WxC50TqTk8.
-
Our vibrant culture at Genmab is part of what makes us extra[not]ordinary®. Our colleagues are encouraged to be their authentic selves and treat each other with a sense of respect and care. Hear from Jesper Lykkesfeldt, Vice President, Head of Legal, Global R&D and Corporate Strategy on his perspective. To be part of the extra[not]ordinary®, visit: https://bit.ly/3LHrGHg.
-
NEWS: Our latest peer-reviewed article on generative #AI is now available in PLOS Digital Health. In research, it’s vital to have accurate and unbiased information to address scientific questions, and our retrieval-augmented generation (RAG) model proved to be a useful system to answer questions specific to diffuse large B-cell lymphoma (#DLBCL) disease biology and treatment. This is an example of how our brilliant team is using data science, AI and predictive analytics end-to-end to generate actionable knowledge and insights to inform our decisions and support our goal of getting innovative antibody therapies to patients. Read more: http://gmab.ly/cOUC50TprYl
-
Genmab genopslog dette
🌟Genmab President & CEO Jan van de Winkel, Ph.D. reflects on 25 years of Genmab! Genmab is an international biotechnology company creating innovative and differentiated antibody therapeutics to improve the lives of patients. #NasdaqListed
-
At Genmab, we are dedicated to advancing antibody medicines through cutting-edge scientific initiatives, and are proud to be working alongside with Texas Medical Center and the Foreign Ministry to drive innovation towards our common goal of improving patients’ lives. Our commitment to enhancing patient outcomes remains at the core of everything we do, and we’re excited about the potential transformative impact the collaboration with TMC. #CancerResearch #Innovation #Healthcare #Collaborations #Genmab #TexasMedicalCenter #DenmarkBiobridge
Great collaborations deserve to be celebrated—and continued! We’re thrilled to announce that our Denmark Biobridge has been renewed for another five years. This new phase brings fresh industry partnerships to advance life sciences, with a focus on cancer, brain health, women’s health, and medical devices. We thank the BioInnovation Institute, the Novo Nordisk Foundation, and Genmab for their commitment to making revolutionary strides toward better patient outcomes. Read the full press release here! https://lnkd.in/g93uYv7g Group photo from left to right: •Emily Reiser, PhD, Director, Strategy & New Ventures, Texas Medical Center •Roberta Schwartz, PhD, EVP and Chief Innovation Officer, Houston Methodist •Louise Dyhrberg, Senior Commercial Advisor, Ministry of Foreign Affairs of Denmark •William McKeon F. McKeon, President & CEO, Texas Medical Center •Sheila Ryan PhD, JD, MPH, CCRP, Assistant Vice President Clinical Research, Research Compliance, Integrity & Grant Policy, Baylor College of Medicine •Ashley McPhail, Chief External Affairs, Texas Medical Center •Dorte Bech Vizard, Deputy Permanent secretary of State for the Ministry of Interior and Health • Vineet Gupta, PhD, Vice President for Innovation, Technology Development, The University of Texas Medical Branch • Joseph Petrosino, Ph.D., Chief Scientific Innovation Officer, Baylor College of Medicine • Sundeep Mattama, PhD, MBA, Executive Director, Office of Technology Transfer, The University of Texas Medical Branch #healthcare #texasmedicalcenter #TMC #ministryofinteriorandhealth #ministryofforeignaffairs #TMCDenmarkBiobridge
-
Robyn Bilmes, Senior Vice President, Head of Medical Affairs, discusses Genmab’s research efforts to potentially address unmet needs in patients with ovarian and endometrial cancers. Learn more about our oncology pipeline: http://gmab.ly/WRmE50Tp4K3. #ESMO24 #Innovation #AntibodyScience
Tilsvarende sider
Finansiering
Seneste runde
Post IPO-egenkapital134.000.000,00 US$